Free Trial
NASDAQ:MIST

Milestone Pharmaceuticals Q3 2024 Earnings Report

Milestone Pharmaceuticals logo
$1.53 -0.01 (-0.65%)
Closing price 04:00 PM Eastern
Extended Trading
$1.52 -0.01 (-0.65%)
As of 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Milestone Pharmaceuticals EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.18
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Milestone Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Milestone Pharmaceuticals Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Milestone Pharmaceuticals' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025

Earnings Documents

Milestone Pharmaceuticals Earnings Headlines

Trump’s SHOCKING Plan to Create MASSIVE Wealth for Americans
James Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presidential decision in modern history. According to his research, this could set off a massive wealth wave—potentially turning a $900 investment into $108,000 in under a year. It has nothing to do with tariffs or trade wars—but it’s already gaining momentum, and the window to act is closing fast.
See More Milestone Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Milestone Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Milestone Pharmaceuticals and other key companies, straight to your email.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals (NASDAQ:MIST), a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

View Milestone Pharmaceuticals Profile

More Earnings Resources from MarketBeat